A significant proportion of men undergoing 'curative' radical prostatectomy (RP) for organconfined prostate cancer relapse within 5 years. A number of adverse risk factors have been identified, but to date no adjuvant treatment as improved the outlook for these men. We proposed that these patients, despite small tumour burdens, may be immunosuppressed from their cancer, which may be amenable to immune modulation. We investigated their immune profile using sensitive functional cytokine assays, both pre-and post-surgery. In comparison with controls, RP patients expressed higher levels of both T helper type 1 (Th1) (interleukin (IL)-2 and tumour necrosis factor-a) and Th2 cytokines (IL-4, -5 and -10) with little change after removal of tumour. Further analysis based on known poor-prognostic factors indicated a trend to expression of higher levels of Th2 cytokines IL-4 and IL-5 in worse prognosis patients rather than the mixed Th1/2 found across the whole cohort. Persistently high levels of both Th1 and Th2 cytokines were detected in RP compared to control patients, despite the removal of relatively small tumour burdens. Cytokine expression studies may be useful as surrogate marker of potential disease progression, and could be used to identify patients who may benefit from immune modulation post-surgery.
Introduction
A large proportion of men undergoing radical prostatectomy (RP) for organ-confined small volume prostate cancer (PC) have been shown to have micrometastatic disease at the time of operation. [1] [2] [3] [4] In addition, certain histological findings such as lymphovascular invasion and involvement of the seminal vesicles are known to be associated with a poorer prognosis. 5, 6 The long-term prognosis for these patients is generally good, but 10% of patients with T3 disease will succumb at 10 years. [7] [8] [9] In addition, half of all patients with clinically localized PC who sustain PSA failure within 2 years of RP will develop distant metastases within 5 years. 10 Immune modulation has been proposed as an ideal adjunct postsurgery in view of its low toxicity. The immunosuppressive effects of cancer, surgery and anaesthesia have been well documented. [11] [12] [13] [14] [15] [16] However, there is little data on the immunosuppressive effects of small disease burdens in localized PC. There is extensive evidence that the immune system recognizes and responds to prostate antigens. This includes the presence of T cells, dendritic cells and macrophages within PCs, 17 the rapid influx of T cells upon androgen deprivation, 18 the identification of numerous T-cell epitopes within proteins expressed by the prostate and the response to immunotherapy for advanced disease. 19 In this study, we have evaluated the effect of organconfined PC on cellular immunity before, and following, radical open surgery. We have employed highly sensitive functional assays for cytokine profiling using stimulated peripheral blood mononuclear cells (PBMCs) taken pre-and post-treatment. The identification of surrogate markers of immune status using peripheral blood samples in this way could define a subset of this population, which may benefit from systemic immunomodulation at a time when the PSA level may be undetectable. We have also quantified the frequency of regulatory T cells (T reg). T reg are a functionally unique population of T cells that normally maintain immune homeostasis. 20, 21 It has been shown that an increasing tumour burden is associated with a significant increase in the proportion of circulating T reg cells in cancer patients and experimental models. 22, 23 T reg have been shown to downregulate the activity of effector function against tumours, resulting in T-cell dysfunction in cancer-bearing hosts. 24, 25 An increased population of T reg has been reported in patients with ovarian cancer, lung cancer and breast cancer. 22, 26, 27 Owing to the immunological effects of general anaesthesia and surgical stress discussed previously, comparison with a control group of patients undergoing non-cancer surgery was made (Tables 1 and 2 ).
Patients and methods
Patients undergoing open retropubic RP for organconfined PC were included. All patients had no concurrent or prior malignancy or inflammatory disease. None of the patients were taking any medication associated with immune modulation such as steroidal or non-steroidal anti-inflammatory drugs. Blood for immunological analysis was taken 1 week before the procedure and 6 weeks postoperatively. For comparative analysis, blood was taken at the same intervals from agematched controls undergoing surgery for conditions other than cancer, but for whom the anaesthetic (general) was directly comparable to patients undergoing RP. None of the patients or controls gave any history of inflammatory or autoimmune disease. General anaesthetic consisted of induction with propofol and a shortacting opioid, with isoflurorane maintenance. Muscle relaxation was achieved with a non-depolarizing agent, atracurium.
Isolation of PBMC
Thirty millilitres of blood was venesected into 3 Â 10 ml sodium heparin blood tubes (BD Vacutainer Systems, Plymouth, UK). In a sterile environment, the blood was diluted 1:1 in phosphate-buffered saline (PBS), and layered onto Histopaque 1.083 (Sigma-Aldrich, Poole, UK) for density-gradient centrifugation in a 50 ml Falcon tube. The tube was then spun at 688 g and 201C for 25 min. The PBMC layer was then removed using a plastic Pasteur pipette and placed into a fresh 50 ml Falcon tube. This was then filled to capacity with Hank's balanced salt solution (Sigma-Aldrich) and spun at 688 g with the deceleration brake set to maximum for 10 min at 201C. The pellet formed at the end of this spin was resuspended in freezing medium consisting of Roswell Park Memorial Institute (RPMI) 1640 with 10% foetal calf serum (FCS), 1% L-glutamine and 10% dimethyl sulphoxide (DMSO; all Sigma-Aldrich). The cells were counted using the Trypan Blue (Sigma-Aldrich) exclusion technique, and frozen overnight in Nalgene Cryo freezing containers (Nalgene, Rochester, NY, USA) at a concentration of 5 Â 10 6 /ml in 1 ml aliquots. The following day, the samples were transferred to liquid nitrogen storage tanks.
Cytokine estimation
Frozen PBMCs were rapidly thawed in a water bath into 9 ml complete medium (RPMI 1640 with 10% FCS and 1% L-glutamine, as before) in a 15 ml Falcon tube and spun at 688 g for 5 min. The pellet was then resuspended in 500 ml complete medium and two 250 ml aliquots were placed in separate wells of a 48-well plate (Greiner, Gloucester, UK).
The plate was then incubated at 371C, 5% CO 2 for 24 h, after which time the stimulants were added. Cells were either stimulated with a combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin, or lipopolysaccharide (LPS). The stimulants were made up in complete medium and 250 ml added to the wells. PMA (Sigma-Aldrich) was used at 0.1 mg/ml, diluted in RPMI 1640 and ionomycin (Sigma-Aldrich) at 1 mg/ml diluted in ethanol (Fisher Scientific, Loughborough, UK). LPS (Sigma-Aldrich) was used at 2 mg/ml diluted in RPMI 1640. The cells were then replaced in the incubator for a further 24 h. Exactly 24 h after the stimulants were added, the contents of each well were harvested into labelled 2 ml Eppendorf tubes. The tubes were spun at 1500 g in a Sigma 1-15 centrifuge for 3 min, and the supernatants harvested. These samples were then frozen at À801C.
Cytokine levels were quantified using the Becton Dickinson tissue helper type 1 (Th1)/Th2 CBA kit (Becton Dickinson, Oxford, UK). The cytokine capture beads have discrete fluorescent FL3 intensities according to their specificities. Ten microlitre of each bead was needed per sample for the assay. The first row of a 96-well plate was labelled as per the standards from nil to top standard, and the rest of the plate labelled according to test samples. Fifty microlitre phycoerythrin (PE) detection reagent was added to each well, and 50 ml capture beads, with the beads vortexed after each aliquot removed. Fifty microlitre standards were added to the labelled wells in the top row of the plate, and the test samples transferred to the relevant wells. PMA/ionomycin supernatants were used at a 1:20 dilution with assay diluent, that is, 5 ml sample and 45 ml assay diluent, and LPS supernatants neat (50 ml). The plate was then incubated for 3 h at room temperature in the dark. High levels of immunosuppressive cytokines in patients after RP N Quatan et al
After incubation, the plate was spun for 3 min at 110 g and the supernatant discarded. The beads were resuspended and 100 ml wash buffer added (supplied with kit). The plate was spun again, supernatant discarded and the beads resuspended in 200 ml wash buffer.
Before flow cytometric analysis on the FACScalibur fitted with a multi-well autosampler (Becton Dickinson), the instruments were set up using PE and fluoresceinisothiocyanate (FITC) controls supplied with the kit. The samples were analysed in the plate, and 1800 events were acquired.
Frozen PBMC were rapidly thawed in a water bath into 9 ml complete medium (RPMI 1640 with 10% FCS and 1% L-glutamine) in a 15 ml Falcon tube and spun at 688 g for 5 min. The pellet was then resuspended in complete medium and incubated overnight at 371C, 5% CO 2 , after which cells were stained with anti-CD4-FITC and anti-CD25-PE-CyChrome and anti-CD152-PE (IgG 1 , BD Biosciences, Oxford, UK) for 30 min on ice. Additional samples were labelled with isotype-matched irrelevant antibodies to account for nonspecific binding. Samples were analysed on a FACSCalibur flow cytometer (BD Biosciences) using CellQuest software (BD Biosciences).
þ T cells were purified by depletion of cells expressing CD14, CD8, CD56, CD19, CD235a and CD45RA. CD25-coated magnetic beads were then used to isolate positively the CD4 þ CD25 þ fraction. The negative fraction, containing CD4 þ CD25 À T cells, was also collected. The purity of these populations was determined by staining with anti-CD4-FITC and anti-CD25-PE antibodies and analysed as described previously. Purity was determined to be in excess of 95 and 90% for the CD4 þ CD25 þ and CD4 þ CD25 À populations, respectively. Isolated cells (3 Â 10 4 /well) were cultured in AIM-V serum-free lymphocyte medium (Invitrogen, Carlsbad, NM, USA) in 96-well round-bottom plates (Costar, New York, NY, USA). For plate-bound anti-CD3 stimulation, 50 ml of the monoclonal anti-CD3 antibody (clone UCHT1, R&D Systems, Minneapolis, MN, USA) diluted in PBS (Sigma-Aldrich) to 0.5 mg/ml were added to each well, placed at 371C for 4 h and then washed twice with PBS, before culturing cells. For costimulation, monoclonal anti-CD28 (clone 37407, R&D Systems) was added to a final concentration of 5 mg/ml in the culture medium.
Statistical analysis
Cytokine expression was compared between cancer and control patients at pre-and postoperative measurements using unpaired t-tests. Paired t-tests were used to compare pre-and postoperative measurements of cytokine expression for the cancer and control groups separately. In the cancer patient group, those with one or more poor prognostic factors were compared to the remaining cancer patients using unpaired t-tests. Given the large differences between the cancer and control groups, the natural logarithm of the cytokine expression measurements were plotted in Figure 1 . 
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Results
Comparison of cytokine profiles between control and study group
Cytokine expression by maximal in vitro PBMC stimulation was measured prior and 6 weeks after surgery for both prostatectomy and control groups. Cytokines were measured in all patients: we did not extract enough lymphocytes for patient 11 post-surgery, hence excluded him from the analysis.
The post-surgery evaluation was deliberately longer than previous studies to allow full haematological recovery from the effects of general anaesthesia. For all patients, high levels (450 000 pg/ml) of interferon-g were detected, and were not significantly different within any of these groups (data not shown). However, there were marked differences between cancer and control patients with respect to four other cytokines. Cancer patients taken as a group appeared to have significantly higher levels of both the Th1 cytokines interleukin (IL)-2 and tumour necrosis factor (TNF)-a, and also the Th2 cytokines IL4, IL-5 and IL-10 compared to controls. Furthermore, there appeared to very little change after surgery, with a trend of increasing TNF-a, Analysis of cancer and control patient groups separately, comparing pre-surgery versus post-surgery, did not show statistically significant differences apart from increase in IL-10 after surgery in the control group (P ¼ 0.01).
Our study uses cytokine production from semipurified cells in vitro to equate to cytokine production in vivo. Serum measurements of cytokines are plagued with difficulties owing to short half-life, soluble receptors, anticytokine antibodies and receptor antagonists. The reproducibility of assays using stimulated cells has been established for many years and is now the 'industry standard' for all immune-based studies. There are correlations between serum-based assays and those using stimulated cells, although the latter are much more reproducible. 28 
Correlation of cytokine profiles with surgical risk factors
The known poor prognostic factors associated with RP include margin positivity, nodal metastases, perineural invasion, etc. We found that 11 of our 17 patients had at least one of these criteria (patients 2, 3, 6, 7, 8, 12, 13, 14, 15, 16, 17) . Comparing these patients as a group to the remaining surgical patients, we found that there was a trend to expression of higher levels of the Th2 cytokines IL-4 and IL-5 (P ¼ 0.076 and P ¼ 0.009, respectively; Figure 2 ), rather than the mixed Th1/Th2 we found in the whole cohort.
Regulatory T cells
Regulatory T cells were selected and defined on the basis of their phenotypic expression: CD25 þ CD4 þ CTLA4 high ( Figure 3) . The normal proportion of T regs of total circulating CD4 þ cells is between 5 and 10%. The majority of patients had normal numbers of T reg, which did not change significantly after surgery in the prostatectomy cohort. Only three patients showed slightly higher levels and there were no correlations with PSA or Gleason grading. T reg numbers were within normal limits in the control patients (data not shown). High levels of immunosuppressive cytokines in patients after RP N Quatan et al
Discussion
There have been a number of reports describing changes in cellular and humoral immunity as a result of cancer surgery, where expression of immunosuppressive factors may be reduced or even reversed. These studies have taken into account the effects of surgical trauma and general anaesthesia involving a range of anaesthetic agents. Surgical trauma is thought to lead to an increase in proinflammatory cytokines, and this may be offset by general anaesthetic, which is considered to be immunosuppressive resulting in an overall shift to Th2. The method of anaesthesia has been shown to have a number of effects on cytokine production. For example, the volatile gas halothane used for the induction of anaesthesia has been shown to decrease TNF-a production, 7 and the intravenous anaesthetic ketamine may have the opposite effect. 8 Evidence exists to suggest that spinal anaesthesia may result in less immunosuppression. 10 In this study, we have found that despite having apparently small volume (tumours of stage T2 or less) organ-confined disease, patients with PC had high levels of both Th1 and Th2 cytokines, which persisted despite removal of the prostate. This was in comparison to the smaller control group who were, on average, 12 years older than the study group. However, the cytokines were measured using a functional dynamic assay using stimulated cells and not a snap shot cytokine level in serum as in a number of older studies. There is no evidence in the literature that the difference in the mean ages of the two groups (as indicated) would affect cytokine expression. Although there is some murine evidence of the effect of age on the cognate function of CD4 þ cells, no similar evidence exists for humans. The assays measure cytokines using the cytometric bead array -essentially 14 (now up to 24) cytokines are measured from each sample: 300 repeats of individual measurements are made in the FACS-based analysis and the assay is highly reproducible with no significant differences between each of the repeats. The issue of paired testing and statistics are addressed. Ref: http://www.bdbiosciences.com/pharmingen/products/ display_product.php?keyID ¼ 9
We performed postoperative bloods 6 weeks postsurgery to allow for the changes in both lymphocyte and neutrophil function well documented in response to surgical and anaesthetic stress. 29 High levels of both INFg were found pre-and postoperatively with no significant differences between cancer and control patients. High levels of IL-2 IL4, IL-5, IL-10 and TNF-a were observed only in the cancer patients, statistically significant for both TNF-a and IL-5. Previous studies have suggested that in patients with significant tumour burdens, the presurgical phenotype tends towards Th2 and that this is reversed with tumour debulking or removal. However, there is considerable inconsistency in these studies in terms of the method of measurement of cytokines (ELISA), evaluation of whole blood, plasma and serum and, importantly, the timing of the postoperative blood sampling. In our study, we used a functional assay to measure cytokine expression, which has a high degree of reliability and reproducibility, and have examined postoperative blood samples at 6 weeks. Our control population of patients undergoing similar anaesthesia showed significantly less expression of both Th1 and Th2 cytokines and these did not change at the 6-week postoperative assessment. When we compared RP patients with at least one poor prognosis factor, we found that, compared to the remainder of the cohort, these patients have persistently high levels of specific Th2 cytokines, IL-4 and IL-5. Our cohort of patients was too small to subdivide into individual groups based on each of the above 'poor prognostic' criteria, and the follow-up would be too short to relate to outcome, although we intend to do this as all patients are still alive and in our centre. The definition of worse or poor prognosis is generally accepted (perineural invasion, positive extensive margins or lymph node metastases).
We found that despite the immunosuppression demonstrated by stimulation studies, the number of circulating T reg remained within normal limits for the majority of the patients. This probably reflects the small tumour burdens in question: increasing tumour burden has been shown to induce higher levels of circulating and intratumoral T reg.
The findings in this small cohort of patients will form the basis of future larger studies. As a high proportion of these patients are known to have micrometastatic disease in the blood and bone marrow, the observation of persistent immunosuppressive cytokine production may not be surprising. However, despite detection of tumour cells in the circulation or bone marrow, a large proportion of the same patients will still have an excellent outcome. Perturbed cytokine expression 6 weeks after surgery may be a useful surrogate marker to define those patients who may be at risk of progressive disease, and who could enter a randomized trial of an immune regulator or adjuvant hormonal or chemotherapy agents. Candidate Th1-inducing agents such as bacillus-Calmette-Guerin (BCG) and low-dose subcutaneous IL-2 would fulfil these criteria, but the minimal toxicity of cancer vaccines make them an attractive strategy in this context.
